Skip to main content
  • World Health Organization Global
  • Regions
    World Health Organization WHO Regional websites
    • Africa Africa
    • Americas Americas
    • South-East Asia South-East Asia
    • Europe Europe
    • Eastern Mediterranean Eastern Mediterranean
    • Western Pacific Western Pacific
  • Countries
    World Health Organization Countries in the WHO South-East Asia Region:
    • Bangladesh Bangladesh
    • Bhutan Bhutan
    • Democratic People’s Republic of Korea Democratic People’s Republic of Korea
    • India India
    • Maldives Maldives
    • Myanmar Myanmar
    • Nepal Nepal
    • Sri Lanka Sri Lanka
    • Thailand Thailand
    • Timor-Leste Timor-Leste
When autocomplete results are available use up and down arrows to review and enter to select.
World Health Organization
South-East Asia
Timor-Leste
Home
  • Home
  • Health topics
  • News
  • Our work
  • Emergencies
  • About us
  • Home/
  • Publications/
  • i/
  • item/
  • The selection and use of essential medicines 2023. Executive Summary of the report of the 24th WHO Expert Committee on Selection and Use of Essential Medicines

The selection and use of essential medicines 2023. Executive Summary of the report of the 24th WHO Expert Committee on Selection and Use of Essential Medicines

24 - 28 April 2023

26 July 2023
 | Executive summary
The selection and use of essential medicines 2023. Executive Summary of the report of the 24th WHO Expert Committee on Selection and Use of Essential Medicines
Download (759.4 kB)

Overview

 

 

This executive summary reports the recommendations made by the Expert Committee on Selection and Use of Essential Medicines for the 2023 update of the WHO Model List of Essential Medicines (EML) and the Model List of Essential Medicine for Children (EMLc). 

The 24th meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was held in Geneva, Switzerland, from 24 to 28 April 2023. The Committee considered 85 applications proposing additions, changes and deletions of medicines, medicine classes and formulation on the Model Lists of Essential Medicines. The Committee evaluated the scientific evidence for comparative effectiveness, safety and cost-effectiveness of the medicines in question. The Committee also considered a review of the age-appropriateness of formulations of essential medicines for children, the AWaRe classification of antibiotics, and other matters relevant to the selection and use of essential medicines.
WHO Team
Essential Medicines (EML), Health Product Policy and Standards (HPS), Medicines Selection, IP and Affordability (MIA), WHO Headquarters (HQ)
Number of pages
31
Reference numbers
WHO Reference Number: WHO/MHP/HPS/EML/2023.01
Copyright
  • Quick links
    • Media centre
    • Head of WHO Office
  • Regional links
    • Data
    • Publications
  • Help
    • Contact us
    • Integrity Hotline
Timor-Leste
Home
Privacy Legal Notice
© 2025
WHO